The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.
Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific.
The exam should be performed on patients with greater than 10 years of life expectancy and between the ages of 50 and 70, with earlier imaging recommended for black men.
Lawmakers have opted against authorizing funding for the Wasteful and Inappropriate Service Reduction Model, citing concerns it will overburden patients and providers.
The collaboration between the chipmaker and Abridge, a developer of generative AI for healthcare, will involve data-sharing to improve Nvidia’s general-purpose models, which in turn will be used to make Abridge’s clinical offerings more efficient.
Anthony Weinert, DPM, said the reputational harm he suffered as a result of the 2019 healthcare fraud charges has left him unable to find work, despite the case being voluntarily withdrawn by authorities.
The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. Humana said a “consortium of investors" is making the buy, but few details were revealed.
MRI-detected signs of cardiac remodeling may tell clinicians a thing or two about a patient's odds of developing certain cancers. Changes in heart muscle mass, for example, were linked to an increased risk of breast cancer.
The NSA independent dispute resolution process was updated by federal agencies on May 28, with the final rule including a slew of changes that affect radiology providers.
A vast majority of patient deaths in the first year after TAVR have nothing to do with heart health. Could care teams be doing more to identify high-risk patients?
The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.
Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific.
